Why Bristol-Myers Squibb May Be a Merger Target Soon
Jana Partners' Barry Rosenstein recently acquired a large stake in Bristol-Myers.
Insurgent fund manager Jana Partners' Barry Rosenstein recently acquired a large stake in Bristol-Myers Squibb (BMY) - Get Report . Jana Partners frequently has launched campaigns and proxy contests. Atlantic Equities says Rosenstein could take issue with BMY's overconcentrated portfolio and its overfocus on one blockbuster cancer therapy.
Jana Partners could also pressure Bristol to be acquired by another drug company.
This article was written by a staff member of TheStreet.
